Combined Medication of Antiretroviral Drugs Tenofovir Disoproxil Fumarate, Emtricitabine, and Raltegravir Reduces Neural Progenitor Cell Proliferation In Vivo and In Vitro

Journal of Neuroimmune Pharmacology

Volumn 12, Issue 4, 2017, Pages 682-692

  Xu, Peipei ^a   Wang, Yingchun ^a   Qin, Zhao ^b   Qiu, Lisha ^a   Zhang, Min ^a   Huang, Yunlong ^a,c   Zheng, Jialin C ^a,c,d  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

FTC; Neural progenitor cells; RAL; TDF

Indexed keywords

CASPASE 3; EMTRICITABINE; RALTEGRAVIR; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

ANIMAL CELL; ANTIRETROVIRAL THERAPY; APOPTOSIS; ARTICLE; BRAIN TISSUE; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CELL VIABILITY; CHEMOLUMINESCENCE; CONTROLLED STUDY; CRYOPROTECTION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA;

AIDS DEMENTIA COMPLEX; ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL PROLIFERATION; EMTRICITABINE; MICE; MICE, INBRED C57BL; NEURAL STEM CELLS; RALTEGRAVIR POTASSIUM; TENOFOVIR;

EID: 85025462758     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-017-9755-4     Document Type: Article

References (35)

1. Aboody KS et al (2000) Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 97:12846–12851. doi:10.1073/pnas.97.23.12846
2. Akay C et al (2014) Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neuro-Oncol 20:39–53. doi:10.1007/s13365-013-0227-1
3. Antinori A et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799. doi:10.1212/01.WNL.0000287431.88658.8b
4. Bhatti AB, Usman M, Kandi V (2016) Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus 8:e515. doi:10.7759/cureus.515
5. Blas-Garcia A, Polo M, Alegre F, Funes HA, Martinez E, Apostolova N, Esplugues JV (2014) Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz. J Antimicrob Chemother 69:2995–3000. doi:10.1093/jac/dku262
6. Bondolfi L, Ermini F, Long JM, Ingram DK, Jucker M (2004) Impact of age and caloric restriction on neurogenesis in the dentate gyrus of C57BL/6 mice. Neurobiol Aging 25:333–340. doi:10.1016/S0197-4580(03)00083-6
7. von Braun A et al. (2014) [Antiretroviral therapy]. Therapeutische Umschau Revue therapeutique 71:461–468 doi:10.1024/0040-5930/a000538
8. Calza L et al. (2015) Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. Infectious diseases (London, England) 47:625-636 doi:10.3109/23744235.2015.1034169
9. Del Guerra FB, Fonseca JL, Figueiredo VM, Ziff EB, Konkiewitz EC (2013) Human immunodeficiency virus-associated depression: contributions of immuno-inflammatory, monoaminergic, neurodegenerative, and neurotrophic pathways. J Neuro-Oncol 19:314–327. doi:10.1007/s13365-013-0177-7
10. Demir M, Laywell ED (2015) Neurotoxic effects of AZT on developing and adult neurogenesis. Front Neurosci 9:93. doi:10.3389/fnins.2015.00093
11. Denton PW et al (2012) Generation of HIV latency in humanized BLT mice. J Virol 86:630–634. doi:10.1128/JVI.06120-11
12. Fischer-Smith T, Rappaport J (2005) Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev Mol Med 7:1–26. doi:10.1017/S1462399405010239
13. Gomes NA, Vaidya VV, Pudage A, Joshi SS, Parekh SA (2008) Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of tenofovir and emtricitabine in human plasma and its application to a bioequivalence study. J Pharm Biomed Anal 48:918–926. doi:10.1016/j.jpba.2008.07.022
14. Gunthard HF et al (2014) Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international antiviral society-USA panel. JAMA 312:410–425. doi:10.1001/jama.2014.8722
15. Heaton RK et al (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neuro-Oncol 17:3–16. doi:10.1007/s13365-010-0006-1
16. Imitola J, Snyder EY, Khoury SJ (2003) Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis. Physiol Genomics 14:171–197. doi:10.1152/physiolgenomics.00021.2002
17. Imitola J et al (2004) Stem cells: cross-talk and developmental programs. Philos Trans R Soc Lond Ser B Biol Sci 359:823–837. doi:10.1098/rstb.2004.1474
18. Jin J et al (2016) HIV non-nucleoside reverse transcriptase inhibitor Efavirenz reduces neural stem cell proliferation in vitro and in vivo. Cell Transplant 25:1967–1977
19. Labarga P (2015) New update of the DHHS guidelines for adults and children. AIDS Rev 17:122
20. Marra CM et al (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366. doi:10.1097/QAD.0b013e32832c4152
21. McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4:543–555. doi:10.1016/S1474-4422(05)70165-4
22. Nath A, Sacktor N (2006) Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 19:358–361. doi:10.1097/01.wco.0000236614.51592.ca
23. Park KI et al (2002a) Global gene and cell replacement strategies via stem cells. Gene Ther 9:613–624. doi:10.1038/sj.gt.3301721
24. Park KI, Teng YD, Snyder EY (2002b) The injured brain interacts reciprocally with neural stem cells supported by scaffolds to reconstitute lost tissue. Nat Biotechnol 20:1111–1117. doi:10.1038/nbt751
25. Rao VR, Ruiz AP, Prasad VR (2014) Viral and cellular factors underlying neuropathogenesis in HIV associated neurocognitive disorders (HAND). AIDS Res Ther 11:13. doi:10.1186/1742-6405-11-13
26. Robertson KR et al (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915–1921. doi:10.1097/QAD.0b013e32828e4e27
27. Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neuro-Oncol 18:388–399. doi:10.1007/s13365-012-0120-3
28. Rockstroh JK et al (2013) Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr (1999) 63:77–85. doi:10.1097/QAI.0b013e31828ace69
29. Sacktor N (2002) The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neuro-Oncol 8(Suppl 2):115–121. doi:10.1080/13550280290101094
30. Saha B, Peron S, Murray K, Jaber M, Gaillard A (2013) Cortical lesion stimulates adult subventricular zone neural progenitor cell proliferation and migration to the site of injury. Stem Cell Res 11:965–977. doi:10.1016/j.scr.2013.06.006
31. Slee EA, Adrain C, Martin SJ (2001) Executioner caspase-3, −6, and −7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276:7320–7326. doi:10.1074/jbc.M008363200
32. Snyder EY, Yoon C, Flax JD, Macklis JD (1997) Multipotent neural precursors can differentiate toward replacement of neurons undergoing targeted apoptotic degeneration in adult mouse neocortex. Proc Natl Acad Sci U S A 94:11663–11668
33. Tatro ET, Soontornniyomkij B, Letendre SL, Achim CL (2014) Cytokine secretion from brain macrophages infected with human immunodeficiency virus in vitro and treated with raltegravir. BMC Infect Dis 14:386. doi:10.1186/1471-2334-14-386
34. Walsh JG, Cullen SP, Sheridan C, Luthi AU, Gerner C, Martin SJ (2008) Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci U S A 105:12815–12819. doi:10.1073/pnas.0707715105
35. Wurzer WJ, Planz O, Ehrhardt C, Giner M, Silberzahn T, Pleschka S, Ludwig S (2003) Caspase 3 activation is essential for efficient influenza virus propagation. EMBO J 22:2717–2728. doi:10.1093/emboj/cdg279